PPIDT00396
Drug Information
| Name | Emapalumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB14724 |
| Type | biotech |
| Indication | Emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.[L4840] The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. As part of the condition profile, there have been reports proving a massive overexpression of interferon-gamma which is thought to drive the immune hyperactivation leading to organ failure.[A38676] This condition is usually developed and present the symptomatic profile within the first months or years of life. These symptoms consist of fever, enlarged liver or spleen and a lower number of blood cells.[L4840] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
10 mg/2mL
|
| Injection | Intravenous |
100 mg/20mL
|
| Injection | Intravenous |
100 mg/4mL
|
| Injection | Intravenous |
250 mg/10mL
|
| Injection | Intravenous |
50 mg/2mL
|
| Injection | Intravenous |
50 mg/10mL
|
| Injection | Intravenous |
500 mg/20mL
|